DUBLIN, November 9, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the "Epilepsy: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
Refractory patients, niche indication expansions, and geographical reach offer room for growth in an otherwise crowded epilepsy market. This report addresses the following questions: - Why do leading antiepileptic drugs retain a large amount of brand loyalty, despite loss of exclusivity and cheap direct competition? - Who are the future market leaders in the treatment of epilepsy? - Which patient subgroups will have the largest impact on epilepsy sales? - What are the drug companies' strategies when penetrating a highly crowded market to achieve profitability? - What are epilepsy's unmet needs that could be addressed by drug companies? Key Topics Covered: FORECAST: EPILEPSY - Executive Summary - Market Overview and Trends - Market Definition and Methodology - Aptiom/Zebinix (eslicarbazepine) - Fycompa (perampanel) - Lyrica (pregabalin) - Potiga/Trobalt (ezogabine/retigabine) - Rikelta (brivaracetam) - Vimpat (lacosamide) - Primary Research Methodology TREATMENT: EPILEPSY - Executive Summary - Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Current Treatment Options - Treatment Dynamics - Unmet Needs in Epilepsy EPIDEMIOLOGY: EPILEPSY - Executive Summary - Disease Background - Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations - Appendix MARKETED DRUGS: EPILEPSY - Executive Summary - Product Overview - Other Marketed Drugs - Product profile: Aptiom - Product profile: Banzel - Product profile: Briviact - Product profile: Fycompa - Product profile: Keppra and Keppra XR - Product profile: Lamictal and Lamictal XR - Product profile: Lyrica - Product profile: Onfi - Product profile: Potiga - Product profile: Vimpat PIPELINE: EPILEPSY - Executive Summary - Clinical Pipeline Overview - Product profile (late stage): Epidiolex - Product profile (late stage): ganaxolone For more information about this report visit http://www.researchandmarkets.com/research/2b7sz6/epilepsy